Guardant Health (GH) is lower today as the market reacts to a recently filed insider-trading disclosure showing an officer sale earlier this week. The filing adds incremental supply/overhang perception and can trigger short-term profit-taking—especially when a stock is trading on momentum rather than a same-day fundamental headline. (stocktitan.net)

A Form 4 posted in the past few days shows an officer sale of 3,832 shares dated April 6, 2026, at a reported price of $92.68, with the filing also flagging the transaction as conducted under a 10b5-1 trading plan checkbox. While 10b5-1 sales are often pre-scheduled, they can still pressure sentiment in the absence of offsetting positive news. (stocktitan.net)

The pullback is happening with the next major calendar catalyst approaching: Guardant Health’s next earnings release is marked for April 30, 2026 (after the close). With earnings nearby, traders often de-risk on any signal that insiders are trimming exposure, even modestly, after a rally. (tipranks.com)

Key near-term swing factors include any additional insider filings, updates that change expectations for 2026 growth, and new commercialization or coverage developments around Guardant’s screening and oncology testing portfolio. Until a fresh fundamental catalyst lands, trading may stay headline- and positioning-driven into the April 30 report. (investors.guardanthealth.com)